Genmab — Marts 2018

Raffles

På AACR har BMS et Abstract #2603 (….colorectal cancer treated with Nivolumab + Ipilimumab in checkmate -142, 16. april). De øvrige drugs (DARA og Cobimetinib) står dog ikke nævnt i overskriften!
Endvidere har de Abstract #1727 (antitumor actitity associated with dual targeting of CD38 and PD-1 pathways in preclinical models, 16. april).
Mon der kommer noget brugbart nyt d. 16. april??

E_L

i wast just reading this one " Furthermore, TTI-622 potentiates the efficacy of daratumumab and cetuximab in hematological and solid xenograft tumor models, respectively" http://www.abstractsonline.com/pp8/#!/4562/presentation/9327

E_L

that is the way to clarify it Bulder, thanks

mobbyduck1

Bergenbio er også med på AACH:

mobbyduck1

Bloomberg - Are you a robot?

(www.bloomberg.com)

mobbyduck1

AACR

Bulder

Checkmate 142 var et studie, der kørte i forvejen, og hvor dara blev hægtet på af BMS. Så der er sikkert ikke data endnu på dara-armen.

E_L

760 / 27 - Conjugation of daratumumab with 225actinium greatly increases its antitumor activity against multiple myeloma tumors
http://www.abstractsonline.com/pp8/#!/4562/presentation/9725

Bulder

Dara + en cd47-blokker - abstract 2709 - mindes jeg ikke at have set før. Til gengæld har vi nu set en del til blokade af pd-1 kombineret med et cd38 antistof.

Bulder

Den der med actinium adc var også med på ASH. Man kunne jo spørge Winkel på næste q&a om han kan se en dara+actinium adc for sig. E L?

E_L

5619 / 14 - Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab http://www.abstractsonline.com/pp8/#!/4562/presentation/8409

Bulder

Der er efterhånden en laang kø af stoffer, der bare længes efter at blive kombineret med dara.

Bulder

Interessant: " the combination of SGN-CD48A with daratumumab produced durable complete remissions in all animals. In contrast, combination of SGN-CD48A with elotuzumab did not produce additional antitumor activity. "

E_L

it will become increasingly difficult to keep track of all; but i guess that really is a luxury-problem

bibob

Next is Dara combined with Heineken.

Bulder

Yes we'll have to wait for the studies to become clinical studies. That will make the overview easier. But really encouraging that there are so many pre-clinical opportunities.

E_L

"no hang-over the day after" - would gaurantee triple-block-buster lol

E_L

2122 / 7 - Induction of structural and functional effects of myeloma cells after daratumumab treatment http://www.abstractsonline.com/pp8/#!/4562/presentation/1807

E_L

1890 / 21 "These results suggest that treatment by inecalcitol may render 95% of AML patients sensitive to highly sensitive to anti-CD38 immunotherapy such as daratumumab." http://www.abstractsonline.com/pp8/#!/4562/presentation/6586

E_L

ok Bulder, i'll save that question for Q&A